Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had stable moderate to severe plaque psoriasis for at least 6 months~* Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.~* Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline.~Exclusion Criteria:~* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis.~* Evidence of skin conditions at the time of the screening visit (eg, eczema, guttate psoriasis) that would interfere with evaluations of the effect of IP on psoriasis.~* Subject has any active CTCAE grade 2 or higher infection~* Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.~* Subject has used the following therapies within 14 days of the first dose: UVB therapy or topical psoriasis therapies other than Class I or II topical steroids~* Subject has used the following therapies within 28 days of the first dose: Class I or II topical steroids, UVA therapy (with or without psoralen), or systemic psoriasis therapies~* Subject has used the following therapies within 3 months of the first dose: adalimumab, alefacept, etanercept, infliximab, certolizumab, or live vaccines~* Subject has used an anti-IL12/IL23 inhibitor within 6 months of the first dose~* Subject has previously used an anti-IL17 biologic therapy, efalizumab, or rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 140 mg SC (Type: EXPERIMENTAL): 140 mg SC
- 70 mg SC (Type: EXPERIMENTAL): 70 mg SC
- 280 mg SC (Type: EXPERIMENTAL): 280 mg SC
- 210 mg SC (Type: PLACEBO_COMPARATOR): 210 mg SC
- Placebo (Type: EXPERIMENTAL): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).